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ABSTRACT
It is now evident that biological agents targeting on the tumor necrosis factor (TNF) have not only induce a sub-
stantial clinical response, but also inhibit the structural damage in patients with Rheumatoid Arthritis (RA). Upon
the great success of anti-TNF biologicals as the therapeutic modalities of choice in the treatment of inflamma-
tory disorders of unknown etiology, the details of TNF, and anti-TNF biological agents are extensively reviewed,
particularly, focusing on those used against RA. So far, nearly one million patients are expected to expose to
these agents worldwide. In Japan, chimeric monoclonal antibody to TNFα, infliximab has been approved for
Crohn’s disease in 2002, RA in 2003, and TNF receptor 2-IgG Fc fusion protein, etanercept had just approved
for RA in 2005. Full human anti-TNFα monoclonal antibody, adalimumab is now under clinical trials. Safety pro-
files of these agents, based on the exposure to one hundred million patients for up to ten years, are summa-
rized. While the experiences using biological agents in Japan are rather limited, the unique circumstances in
Asian countries should been taken into account. In this respect, the issues around the anti-TNF biologicals in
Japan are finally discussed.
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INTRODUCTION
Tumor necrosis factor (TNF) was first isolated in
1975, as a factor with the potential to kill tumor cell
lines in vitro.1 In addition, two other factors with simi-
lar physiological activity were identified, and desig-
nated as lymphotoxin α and β (LT-a, LT-b).2-4 TNFs
are believed to play an important role in host defense
against infections and tumor development . 4,5 How-
ever, accumulating evidence has suggested that over-
production of TNFs is closely related to the patho-
genesis of inflammatory disorders such as rheuma-
toid arthritis (RA), Crohn’s disease, and other inflam-
matory diseases . 6,7 Subsequently , much effort has
gone into the development of therapeutic agents ,
which target TNFs. These efforts have resulted in
anti-TNF biological agents , which have shown dra-
matic improved outcomes in RA patients as well as in
patients suffering from other inflammatory disorders
of unknown etiology . 8,9 These biological agents ,
which directly target the inflammatory cytokines
have revolutionized our strategy in the management
of such diseases.10
ACTION AND STRUCTURE OF TNFα
TNF binds to specific TNF receptors ubiquitously ex-
pressed on the surface of cells throughout the body,
and has a long list of physiological actions.4,5 An ex-
cess amount of TNFα in the serum can alter the anti-
coagulant activity of the endothelial cells and rewul in
the induction of hemorrhage, vasodilatation, and neu-
trophil activation , all prominent features of septic
shock. On the other hand, a small but significant in-
crease in the long term concenration of TNFα may
evoke inflammatory responses, such as fever , ane-
mia, body weight loss , and even osteoclast activa-
tion.7
Among tumor necrosis factors, TNFα and TNFβ
Allergology International. 2005;54:191-202
REVIEW ARTICLE
1Division of Rheumatology, Saitama Medical Center , Saitama
Medical School, Saitama, Japan. 2Emeritus Professor , Saitama
Medical School.
Correspondence: Tsutomu Takeuchi, Division of Rheumatology,
Saitama Medical Center, Saitama Medical School, 1981 Tsujido-
machi, Kamoda, Kawagoe, Saitama 350−8550, JAPAN.
Email: tsutake@saitama−med.ac.jp
Received 5 March 2004.
2005 Japanese Society of Allergology
Allergology International Vol 54, No2, 2005 www.js-allergol.gr.jp 191
Table 1 Biological agents targeted on tumor necrosis factor
antibody mouse human PEG
PEG-TNFαFab
CDP870
full human anti-TNFα
adalimumab
humanized anti-TNFα
CDP571
chiemric anti-TNFα
infliximab
receptor: Fc fusion protein TNFR human IgG Fc PEG
PEG-TNFR Ⅰ: FcTNFR Ⅰ: Fc
lenercept
TNFR Ⅱ: Fc
etanercept
Table 2 Approval status of anti-TNF biological agents
・infliximab
　Crohn’ sdisease : 98 USA, 98 EU, 02 JAPAN
　RA : 99 USA, 00 EU, 03 JAPAN
　Ankylosing spondylitis : 03 EU
・etanercept
　RA : 98 USA, 00 EU, 05 JAPAN
　JIA : 99 USA, 00 EU
　Psoriatic arthritis : 02 USA
　Ankylosing spondylitis : 03 USA, 03EU
・adalimumab
　RA : 02 USA
(a.k.a : lymphotoxinα), and lymphotoxin β have been
previously identified . 4 These three molecules are
generated from three distinct genes on the chromo-
some 3 and act as trimers , binding to receptors ,
which also consist of homotrimers.5 TNFα consists of
homotrimers of TNFα, TNFβ consists of homotrim-
ers of TNFβ (LTα), and lymphotoxinB is a combined
from of LT-α and LT-β1. TNFα and TNFβ can bind to
two kinds of TNF receptors, namely TNF receptor I
(p55) and TNF receptor II (p75). The unique het-
erotrimers, consisting of two molecules of LT-α and
one molecule of LT-β binds to the third receptor, des-
ignated as LT-βR. It has long been thought that each
of the receptor molecules exists independently, and
assemble during ligand binding. This model is known
as the “ ligand-induced trimerization” model . Since
signal transduction occurs independently, depending
on the individual class of receptor,11 it is widely ac-
cepted that a single receptor is primarily assembled
as a trimer. This pre-ligand assembly model is now
recognized as the correct process since a pre-ligand
assembly domain (PLAD) has been identified.12
The majority of TNFα is produced by a variety of
cells including monocytesmacrophages, T cells, B
cells, and keratinocytes.5 Upon stimulation, signals
are transduced from the cell surface receptors into
the cytoplasm,11 ultimately leading to activation of the
transcription factors and binding of the promoter re-
gion of the targeted genes which initiates final tran-
scription of TNFα. Regulation of the stability of the
messenger RNA (mRNA) for TNFα is controlled by
stabilizing factors and destabilizing factors , which
bind the AU-rich region located within the 3’ untrans-
lated region (UTR) of mRNA. One of the stabilizing
factors is HuR, while TIA-1 acts as a destabilizing fac-
tor. Thus TNFα is produced with the transmembrane
domain is transported to the surface of the cell mem-
brane, and expressed on the cell surface. When mem-
brane proteases such as TNF-α Converting Enzyme
(TACE) are activated in pathological conditions or
MT-MMP in physiological conditions cleave TNF-α
on the cell surface, the end result is the release of
free TNF-α.5
ROLE OF TNF-α IN THE PATHOGENESIS OF
RA
Early experiments have demonstrated that RA
synovial cells produced an excess amount of TNF-α
in vitro, and anti-TNF-α monoclonal antibody inhib-
ited not only TNF-α, but also subsequent production
of IL-1, IL-6, and IL-8. These findings suggest that
TNF-α is located upstream of the cytokine cascade.6,7
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Fig. 1 Action of anti-TNF biological agents
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To test the hypothesis that TNF-α plays a pivotal role
in RA pathogenesis, TNF-α transgenic (tg) mice were
generated. Results showed that erosive polyarticular
arthritis developed in the TNF-α tg-mice, and block-
ade of TNF-α significantly reduced both the severity
and even the development of arthritis, in addition to
associated structural damage . Furthermore , it was
demonstrated that the anti-TNF-α monoclonal anti-
body could ameliorate a collagen-induced type of ar-
thritis . These results have provided evidence for a
TNF blockade strategy, which has facilitated the de-
velopment of a clinical application of this approach in
the management of inflammatory arthritis.13
BIOLOGICAL AGENTS INHIBITING THE AC-
TIVITY OF TNF-α
Several strategies for the production of biological
agents, designed to inhibit the activity of TNF-α have
been adopted . There are two major categories of
such agents : one is a monoclonal antibody, and an-
other is a receptor-antagonistreceptor-Fc fusion pro-
tein . Table 1 show the monoclonal antibodies such
as , the chimeric monoclonal antibodies to TNF-α
(clone cA2, inflixiamab : Remicade),14 humanized
mAb (CDP571) , 15 full human mAb (clone D2E7,
adalimumab : Humira),16 and the polyethylene gly-
col (PEG)-Fab fragment (CDP870). Receptor antago-
nistreceptor-Fc fusion proteins-include, the TNF re-
ceptor II-Fc fusion protein (etanercept : Enbrel) ,
the TNF receptor I-Fc fusion protein (lenercept), and
the PEG-TNF receptor I.17 Infliximab, adalimumab,
and etanercept have been approved for clinical use in
the United States. Table 2 shows the approval status
of these products worldwide . The first biological
agents approved for the treatment of RA was etaner-
cept in 1998, followed by infliximab in 1999 in the
United States of America. In the year 2002, infliximab
was approved for induction into the Japanese market
for the treatment of Crohn’s disease, followed by ap-
proval for treatment of RA in 2003.
The indications of for use of etanercept include RA,
JIA,18,19 psoriatic arthritis,20 and ankylosing spondyli-
tis,21,22 whereas those for infliximab are RA, Crohn’s
disease,23,24 psoriatic arthritis,25 and ankylosing spon-
dylitis.26-28
EFFICACY OF THE BIOLOGICAL AGENTS
Infliximab : This chimeric mAb consists of a variable
region of mouse immunoglobulin (Ig), which binds to
TNF-α with high affinity (Ka = 1.8 × 109), and the Fc
portion of human IgG1 (Table 1 & Fig. 1)．
SINGLE INFUSION TRIAL
The first clinical trial of infliximab was carried out in
severe RA patients who had not responded to conven-
tional DMARDs. In this study a single infusion at 5―
20 mgkg clearly showed a striking improvement in
the reduction of signs and symptoms.14 Due to the
gradual decrease in the serum concentration of in-
fliximab and total disappearance at 3―4 weeks post-
infusion , the disease activity returned to the pre-
treatment level , suggesting that repeated infusions
are required to control long-term disease activity．
REPEATED INFUSION WITHOUT MTX
Clinical trials with repeated infusions of infliximab in
RA patients has demonstrated that the intervals be-
tween infusions became shorter when infusions were
repeated more than several times . 29 It is assumed
that the development of the human antibody to chi-
meric monoclonal antibody (HACA) was interfering
with the infliximab activity,30 thereby shortening the
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Fig. 2 Clinical response of anti-TNF biological agents (ACR responding rate)
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intervals of the infusion to maintain the efficacy.
DOSE RANGING STUDY WITH OR WITHOUT
MTX
Exciting clinical evidence by Maini et al. has shown
that low doses of infliximab such as 1 or 3 mgkg in
combination with MTX showed a clinical response
comparable with that of high doses of infliximab (10
mgkg) alone . 31 The dose sparing effect of MTX
could be attributed to immunosuppression of HACA
production. Indeed, in the MTXinfliximab combina-
tion therapy, the frequency of HACA detected in the
serum of the patients was significantly lower than in
those patients treated with infliximab alone.
COMPARISON STUDY BETWEEN MTX ALONE
AND MTX+INFLIXIMAB (ATTRACT)
To prove the efficacy of infliximab and MTX combina-
tion therapy, the Anti-Tumor Necrosis Factor Trial in
Rheumatoid Arthritis Concomitant Therapy ( AT-
TRACT) study was conducted in 428 patients with se-
vere RA, who did not respond to MTX with a dose of
more than 12. 5 mgweek.32 After 54 weeks, the pa-
tients treated with MTX+Placebo infusion showed
only a 17% response, whereas all of the infliximab
treated group showed a significant response, 56% of
the patients achieving the ACR 20% response
(Fig. 2 ) . 33 Surprisingly , the mean change in the
modified sharp score , which represents the semi-
quantitative measure of bone and cartilage destruc-
tion, showed more than 7 in the placebo group (only
MTX), while it was markedly suppressed to less than
1 in all the infliximab treated groups.33 These results
suggest that infliximab in combination with MTX not
only reduces the signs and symptoms of RA, but also
strongly inhibits the radiographic progression of
structural damage.32,33
JAPANESE TRIAL
In Japan, a clinical trail with a similar design was car-
ried out in three groups with MTX + placebo, MTX +
infliximab (3 mgkg), and MTX + infliximab (10 mg
kg) at 0, 2, and 6 weeks, and demonstrated a signifi-
cantly better clinical response in the infliximab
treated group. The ratio of patients treated with in-
fliximab 3 mgkg to the ACR20% responding criteria
was 61% at 14 weeks.34 When the Japanese trial data
was compared to the results observed in the AT-
TRACT study, the Japanese trial exhibited a slightly
better result (∆ACR 20% [{that in MTX + infliximab} −
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{that in MTX placebo}]) at week 14 : 34% in the Japa-
nese trial vs the ATTRACT study. One of the major
distinctions between Western countries and Japan is
the maximum dosage of MTX, which is 8 mgweek
in Japan, raising the possibility that Japanese RA pa-
tients with a lower maximum doses of MTX would
have milder disease activity than their Western coun-
terparts, and thus demonstrating a better response to
infliximab.
COMPARISON OF MTX + PLACEBO, AND MTX +
INFLIXIMAB IN EARLY RA
MTX alone or two doses of infliximab (3 mgkg, or 6
mgkg ) with MTX were compared in early active RA
(less than 3 years after onset of RA) with poor prog-
nostic factors . After 54 weeks , the combination of
MTX and infliximab at any doses exhibited a signifi-
cantly high ACR 20, 50, and 70% response, as well as
a significantly smaller increases in the total sharp
score, indicating that the effect of the combination
therapy on early active RA is superior to that of MTX
alone . The numbers of total and severe adverse
events were comparable among the three treatment
groups , supporting the idea that the combination
therapy should be considered in the treatment of
early active RA with a poor prognosis, where the ra-
diographic structural damage is progressing rapidly,
leading to a profound irreversible disability.35
Etanercept : Etanercept is a genetically engineered
protein consisting of two molecules of the extracellu-
lar domain of TNF receptor II (p75) and Fc fragment
of IgG1 (Fig. 1 & Table 1).
DOSE RANGING STUDY
In an earlier study, the effects of placebo and etaner-
cept 0.25 mgm2, 2 mgm2, and 16 mgm2 were com-
pared in 180 RA patients, who had demonstrated a
lack of efficacy to therapy with between one and four
of the previous DMARDs. After 3 months of treat-
ment, a significant reduction of disease activity was
observed in the etanercept treated-group, and dose-
related therapeutic effects were confirmed . In RA
treated with 16 mgm2 of etanercept, 75% of the pa-
tients achieved the 20%ACR response, whereas the
placebo group produced only 14% response.36
PLACEBO-CONTROLLED TRAIL (PLACEBO, 10
MG, 25 MG)
Thereafter, a randomized placebo-controlled trail us-
ing fixed etanercept doses such as 10 mg and 25 mg
twice a week for 24 weeks was designed and carried
out in 234 patients with active RA for 6 months. Re-
sults showed a profound reduction of all the core set
variables in the etanercept group, and the 20%ACR re-
sponse was 59% in the etanercept treated-group (25
mg twice a week), and only 11% in the placebo group
(Fig. 2).37
ADD-ON STUDY TO MTX
A further study was carried out to examine the effi-
cacy of Etanercept in patients with inadequate re-
sponse to a stable dose of MTX. In the group treated
with etanercept 25 mg twice a week, the 20%ACR re-
sponse rate was 71%, while placebo produced a 27%
response, indicating that etanercept is also exhibiting
a significant benefit in RA with MTX inadequate re-
sponders (Fig. 2).38 The follow up studies showed a
sustained clinical response for up to three years.39
COMPARISON OF MTX AND ETANERCEPT IN
EARLY RA
To test the efficacy of etanercept in early RA, a direct
comparison between etanercept and MTX was car-
ried out in 632 patients, diagnosed as having RA for
no more than 3 years and no prior treatment with
MTX.40 The patients were divided into three groups
consisting of MTX (n = 217), 10 mg etanercept (n =
208) , and 25 mg etanercept (n = 207 ) . MTX was
started with a weekly dose of 7.5 mg, followed by an
increase up to 15 mgw at week 4, and 20 mgw at
week 8 with folic acid supplementation (1 mgday).
After the second dose escalation, the mean dose of
MTX was only 19 mgweek, because 15% of the pa-
tients needed to reduce the dose due to adverse
events. After 24 weeks, patients treated with 25 mg of
etanercept showed a more rapid improvement, more
ACR20% , 50% , and 70% response rates over MTX
treated patients . 40 Radiographic evaluation revealed
that the mean increase in the erosion score was 0.30
in patients treated with 25 mg of etanercept, and 0.68
in MTX group , whereas joint-space-narrowing was
comparable between the two groups.40 A two year fol-
low up study demonstrated that the mean changes in
the total sharp score in the 25 mg etanercept group
were significantly lower than those in the MTX group
(1.3 and 3.2, respectively), suggesting that etanercept
acted more rapidly to reduce the clinical parameters,
and retard joint damage in early active RA.41
COMPARISON OF MTX , ETANERCEPT , AND
MTX + ETANERCEPT IN EARLY RA ( TEMPO
STUDY)
In 682 early active RA (less than 3 years), patients
treated with MTX+etanecept showed a significant
high ACR70% response and a high clinical remission
rate according to the DAS definition, in addition to a
significantly low mean sharp score below zero, com-
pared with the groups on MTX and etanercept alone.
These remarkable results indicate that the combina-
tion can achieve remission in a much higher propor-
tion in early active RA patients with a poor prognostic
profile than MTX alone or even etanercept alone, and
furthermore it may arrest or even repair the struc-
tural damage.42
Adalimumab : Adamimumab is a full human mono-
clonal antibody of IgG1, which binds to TNF-α with
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Table 3 Incidence of tuberculosis in patients with anti-TNF biologicals62
AdalimumabEtanerceptInfliximab
2,500 150,000 200,000 number of pts
4900 pts・yr230,000 pts・yr230,000 pts・yrpts・year
13 38 172 number of Tb
60%90%64%USAareas used
40%10%36%non-USA
3 20 55 USAareas developed
10 18 117 non-USA
3―8 month
1―22 months（Median 
11.2）
75%: within 6 week
97%: within 7 month
onset after infusion
40%50%45%extra-pulmonary/miliary
high affinity (Kd = 6 × 10−10M). The antibody with the
clone name of D2E7 is made by the phage display
method with amino acid sequencing from the human
germline (Table 1 & Fig. 1)．
COMPARISON OF PLACEBO AND SEVERAL
DOSAGES OF ADALIMUMAB
Two hundred and eighty-four active RA patients, who
had not responded to DMARDs, were randomly as-
signed to receive weekly subcutaneous injections of
adalimumab (20 mg, 40 mg, or 80 mg) or placebo
without concomitant DMARDs for 12 weeks .
Adalimumab significantly improved the signs and
symptoms of RA with significant better ACR20% re-
sponse rates (20, 40, 80 mg for 50.7% , 57.1% , and
54.2%, respectively, versus 10.0% for placebo)16 (Fig.
2)．
MTX ADD-ON TRIAL (ARMADA STUDY)
Two hundred and seventy-one active RA patients
were randomly assigned to four treatment arms of
placebo + MTX, 20 mg, 40 mg, and 80 mg of adlimu-
mab every other week over 24 weeks.43 The patients
were active even though a sufficient dose of MTX
(12.5―25 mgw or 10 mg if intolerant to higher
doses) was administrated for at least 6 months. All of
the adalimumab treated groups showed a signifi-
cantly higher ACR20% and 50% response rate than
that in the placebo group (Fig. 2).43 Furthermore, the
ACR70% rate in the 40 mg and 80 mg groups was sig-
nificantly higher than in the placebo group. These re-
sults suggest a rapid and sustained improvement
over 24 weeks compared with MTX alone, although
the effect on radiographic progression was not docu-
mented in this trial.
Summary of the three anti-TNF biologics (Fig. 2) :
The efficacy of the above three agents in the ad-
vanced RA patients who have had an inadequate re-
sponse to MTX appears to be comparable , demon-
strating approximately 60% of ACR20, 40% of ACR50,
and 20% of ACR70.44 As illustrated in the 2002 update
version of the ACR guideline for the management of
RA, the biological agents are now positioned as an-
chor drugs.45 Based on these results in early active
RA patients, evolving evidence of dramatic efficacy,
which could pave the way for a hypothesis for the use
of combination of biologic agents with MTX directed
at arresting the disease in the early course RA pa-
tients with a poor prognostic profile, is within the win-
dow of opportunity in the foreseeable future.46
SAFETY
Generally, biological agents are well tolerated, and
safe in most patients. Frequent, but less severe side
effects with standard management have been re-
ported . While infliximab has been used in over
500,000 patients and etanercept in 200,000 patients
worldwide, few, but severe adverse events have accu-
mulated. The individual events are listed as follows.
INFUSIONINJECTION REACTIONS
Infliximab has been associated with infusion reac-
tions , which are rare severe events such as life-
threatening anaphylaxis reactions . The lower the
dose of MTX or infliximab, the higher the rate of
HACA production.47 In previous studies in Western
countries, the minimum dose of MTX against HACA
production was 7.5 mgweek and that of infliximab
was 3 mgkg. In clinical trails in Western countries,
the frequency of infusion reactions has been reported
to be around 5%48 while that of placebo infusion was
2.0%. The patients with infusion reactions leading to
withdrawal accounted for 2.5%, and those with seri-
ous infusion reactions were 0.8―3%. In Western coun-
tries at a does of more than 7.5 mgweek, HACA can
be detected in up to 10% even with the concomitant
usage of MTX. There was a concern that the fre-
quency of infusion reaction and HACA production
would be higher in Japan, since the average dose of
MTX used in Japan has been much lower than that in
Western countries. However, the frequency of infu-
sion reaction and HACA production was comparable
between Western countries and Japan , suggesting
that the minimum weekly MTX dose of 6 mg in the
Japanese clinical trial would have an immunosuppres-
sant effect similar to those doses used in Western
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・Rheumatic diseases
　　polymyositis/dermatomyositis, systemic sclerosis, 
systemic lupus erythematosus98
　　polumyalgia rheumatica91, adult stil’ sdisease92
Wegener’ sgranulomatosis82―84, giant cel arteritis 
86, 87, systemic vasculitis85
・Inflammatory diseases
　　Behcet’ sdisease, secondary amyloidosis90, ul-
cerative colitis93
・Immunological diseases
　　graft versus host disease94
・Granulomatous diseases
　　saocoidosis88, 89
・Hematologic diseases
　　myelodysplastic syndrome95, multiple myeloma96
・Fibrotic diseases
　　interstitial pneumotitis97
Table 4 Possible targets by anti-TNF biological agents
countries.
On the other hand, injections of etanercept may
lead to local reactions, reportedly in 40―45% of pa-
tients.49 The reactions have usually been mild, and
most of them appear to resolve spontaneously or with
appropriate management such as rotation of the injec-
tion site or anti-histamines. It has been shown that
anti-neutralizing antibodies have never been devel-
oped , although anti-etanercept antibodies could be
detected to some extent．
It is interesting to note that human anti-human anti-
bodies (HAHA) or anti-idiotypic antibodies could be
detected in patients treated with adalimumab, and the
frequency appears to be 1―12%. Furthermore, anti-
neutralizing antibodies have been observed with a
frequency of around 5% , in spite of the fact that
adalimumab is a full human genetically engineered
product. Concomitant use of MTX should reduce the
frequency, as in the case of infliximab．
INFECTIONS
A series of basic experiments have indicated that
blockade of TNF-α results in serious infectious dis-
eases caused by intra-cellular pathogens such as My-
cobacterium, 50-53 Pneumocystis carinii 54 and other
fungi,55 legionella,56,57 and Listeria monocytogenesis.58
In the ATTRACT study, the frequency of infection
was 40% in MTX used alone, while it was 50% in the
MTX + infliximab combination group, with no statisti-
cally significant difference.59 The frequency of seri-
ous infection between patients treated with MTX
alone and that with MTX + infliximab was almost the
same. Similarly, the rate of infection in etanercept-
treated patients was 50―60%, which was similar to
those in the control population.59 Again, the risk for
serious infection was comparable between the gen-
eral population and etanercept treated patients. How-
ever , the incidence of severe infections in patients
treated with anti-TNF biologicals in the clinical set-
ting, though not clinical trials, has been reported to
be high with less signs and symptoms.60Mycobacte-
rium tuberculosis had been reported in three patients
in major clinical trials including ATTRACT, ACCENT,
and PROMPT.
However , a post-marketing survey revealed that
the incidence of tuberculosis would be high in RA pa-
tients treated with MTX + infliximab, particularly in
Europe . 61,62 Until August 23, 2002, 277 cases had
been reported to the FDA63Arthritis, # 132 Arthritis. , # 132,
while infliximab was used in 365,201 with the relative
risk of around 7% in the general population .64
Seventy-five percent of these patients developed tu-
berculosis within the first 6 weeks (3 infusions), and
the incidence was higher in endemic regions, sug-
gesting that its appearance was due to reactivation of
latent tuberculosis. 64 Although the incidence of tu-
berculosis in RA patients treated with etanercept ap-
peared to be at the upper limit of the normal con-
trols.65 It is reported that the risk can be seen in pa-
tients treated with adalimumab (Table 3). Since in-
fliximab and adalimumab are believed to lyse TNF-
expressing macrophages (Fig. 1), which play an in-
dispensable role in host defense against Mycobacte-
rium infection,64 the incidence may be higher in pa-
tients treated with infliximab and adalimumab. Given
the observation that the onset is 11 months after
starting etanercept, we need to pay close attention to
the incidence of tuberculosis in the long-term treat-
ment of patients treated with all of the biological
agents including etanercept. Considering the relative
high risk for tuberculosis, the PPD skin test has been
recommended to rule out latent tuberculosis infec-
tion.64,65 Following implementation of this screening,
the incidence of tuberculosis in patients being treated
with anti-TNF biologicals was reportedly even lower
than in prior studies.62 Given the high incidence of tu-
berculosis in Japan, with 30 out of 100,000 in 2001,
which is one of the highest among most of the indus-
trialized nations, where it is less than 10100,000, it
can be assumed that the estimated increased risk of
tuberculosis in Japan is up to 7 × 30100,000. In this
respect, guidelines for the prescription of infliximab
in Japan have been proposed by the study group of
Ministry of , health , labor , and welfare (MHLW)at
2003.66 (Table 5), and have been used in Japan for a
post-marketing survey of all RA cases. Six cases of tu-
berculosis have been reported in the initial one thou-
sand cases for six months observation.67 In addition,
six cases of Pneumocystis carinii pneumonia were re-
ported . Although those patients were treated with
successful resolution of the condition, we need to pay
attention to other opportunistic infections such as
those caused by fungi including P. carinii 68 in addi-
tion to mycobacterial infection, and look at the simi-
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Table 5 Japanese Guidelines for the use of infliximab of RA proposed by study group of RA, MHLW.
Indications:
Active RA despite previous treatment with MTX (Rheumatlex)(≥3 months with MTX ≥6 mg/w). The folowing 3 items are 
satisfied.
1. ≥6 painful joints
2. ≥6 swolen joints
3. CRP ≥20 mg/L or ESR ≥28 mm/hr
As a patient who has low risk of opportunistic infections. The folowing 3 items should be satisfied. 
1. WBC, ≥4000/mm3
2. Total lymphocyte count, ≥1000/mm3
3. β-D-glucan negative
Contraindications:
1. Active infectious disease
2. History of a serious infection during the past 6 months
3. Chest X-rays showing old TB (e.g. Calcification shade ≥5 mm)  
4. Latent TB. When the cases where benefit outweigh risks, medication of Remicade is considered after treatment of TB.
5. History of ex-pulmonary TB, Carini pneumonia
6. Congestive heart failure
7. Malignant tumor, demyelinative disease 
Cautions:
A. Folowing items are important, because for screening of Infection (TB, opportunistic infections) and side efects.
1. Chest X-rays can be taken within the same day. And it can be read by Pulmonologist or Radiologist.
2. Opportunistic infective disease can be treated.Evaluate risk through an interview, tuberculin test, chest X-ray, and chest 
CT scan etc.
B. The caution and preparation for an infusion reaction (including anaphylactic reactions) is required.
 The institution which can cary out an emergency treatment: Keep air-way, Oxygen, Epinephrine, Corticosteroids, etc.
larities and dissimilarities of the opportunistic infec-
tions between Western countries and Japan.
AUTOIMMUNITY
It has been reported that infliximab and etanercept
can induce production of anti-nuclear antibodies and
anti-DNA antibodies , although the titer of the anti-
bodies remains low.69,70 In the earlier studies, the in-
creased risk for developing SLE had been seriously
considered. However , the incidence of the disease
has not been significantly elevated in the treatment
group and it is not a severe life-threatening disease
even if it does develop.71-74 On the other hand, the
risk for demyelinating diseases such as multiple scle-
rosis and optic neuritis75,76 appears to be high, and
TNF blockade therapy is contra-indicated in patients
with these diseases. Curiously, a recent clinical trial
on the chronic inflammatory demyelinating diseases
suggests a significant positive clinical response . 77
The changed cytokine environment, which is largely
skewed by anti-TNF biologicals , is believed to ac-
count for the change in the profile of autoantibody
production and the phenotype of the autoimmune dis-
eases．
MALIGNACIES
As mentioned above, TNF-α has been identified as a
factor inducing tumor cell lysis in vitro. Thus, one
may wonder whether a blockade of TNF-α would re-
sult in an increase in the incidence of malignancy. So
far the incidence of non-hematological malignancies
has been demonstrated to be comparable with the
general population , while that of malignant lym-
phoma may be higher in patients treated with anti-
TNF biologicals.78 Agent due to evidence that the in-
cidence is higher in RA, more active disease , and
MTX users, the risk is not simply attributed to bio-
logical agentes alone. We still need to follow up the
incidence carefully over an extended period.
CONGESTIVE HEART DISEASES
Since it has been proposed that TNF-α has a role in
the pathogenesis of heart failure, clinical trials of in-
fliximab and etanercept have been conducted for pa-
tients with congestive heart failure.79 In contrast to
the earlier expectation, the mortality rate in patients
using higher amounts of infliximab has become evi-
dently higher than that of the placebo group,79 and no
significant benefit was reported in the etnaercept
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treatment group.80,81 These results indicate that anti-
TNF biological agents are not appropriate for the pa-
tients with congestive heart failure．
ANTI-TNF THERAPY IN OTHER DISEASES
(TABLE 4)
Following the great success of anti-TNF biological
agents as the therapeutic modalities of choice in the
treatment of inflammatory disorders of unknown eti-
ology, their possible application in the treatment of
other diseases is now being explored, including in a
long list of diseases such as Wegener’s granulomato-
sis82-84 and other types of vasculitis,85-87 sarcoidosis,
88,89 amyloidosis , 90 polymyalgia rheumatica , 91 adult
Still’s disease,92 ulcerative colitis93 graft vs host dis-
ease,94 myelodysplastic syndromes,95 multiple
myeloma , 96 interstitial pneumonitis , 97 Behcet’s dis-
eases, polymyositis, dermatomyositis, systemic scle-
rosis, and even SLE.98
FUTURE PERSPECTIVES
It is now clear that the usefulness of anti-TNF biologi-
cal agents in combination with MTX or other biologi-
cal agents lies not only in inducing clinical remission
but also arresting structural damage in early RA.41
These results have led to the introduction of a new
strategy whereby powerful combination therapy is ap-
plied to early RA as an induction regimen. To take ad-
vantage of this strategy, we need both to be able to
identify patients who have a poor prognosis and to
have access appropriate powerful treatment regi-
mens. In this regard, remission can be expected to be
induced in 40% of patients with MTX+anti-TNF bio-
logical agents , implying the presence of both re-
sponders and non-responders to the regimen. It has
been demonstrated that −308 polymorphism at the
promoter region of TNF-α could be a predictive
marker for responders to TNF blockade therapy,99
while others reported results to the contrary,100 Simi-
lar approaches are used in Crohn’s disease.101-103
Given that we can now have biological agents tar-
geting TNF, IL-1 and IL-6 as cytokines, CD20, and
CTLA-4 as cell surface structures, it is necessary to
predict the responders to each biological agents be-
fore treatment or after early inhibition of biological
agents, so that we can avoid toxicity of the drugs in
non-responders , and provide efficientl treatment to
the right patients . Comprehensive profiling of the
mRNA expression strategy has recently been started
to identify and predict possible responder candidates.
If we can identify the prediction markers, then tailor-
made therapy using several biological agents may
soon be a clinical reality . Finally , issues of correct
treatment dose and duration for use of anti-TNF bio-
logical agents in these inflammatory disorders re-
mains to be considered.104,105
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